,회사코드,회사명,종목코드,사업연도,접수번호,보고서코드,재무구분,재무구분명,재무제표구분,재무제표명,계정명,당기명,당기일자,당기금액,전기명,전기일자,전기금액,전전기명,전전기일자,전전기금액,순서,통화
333,781202,애머릿지,900100,2015,20160429000770,11011,CFS,재무제표,IS,손익계산서,매출액,제 38 기,2015.01.01 ~ 2015.12.31,"53,519,782",제 37 기,2014.01.01 ~ 2014.12.31,"50,119,479",제 36 기,2013.01.01 ~ 2013.12.31,"44,068,871",24,USD
334,781202,애머릿지,900100,2015,20160429000770,11011,CFS,재무제표,IS,손익계산서,영업이익,제 38 기,2015.01.01 ~ 2015.12.31,"-1,026,046",제 37 기,2014.01.01 ~ 2014.12.31,"778,385",제 36 기,2013.01.01 ~ 2013.12.31,"-768,796",26,USD
335,781202,애머릿지,900100,2015,20160429000770,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 38 기,2015.01.01 ~ 2015.12.31,"-4,114,012",제 37 기,2014.01.01 ~ 2014.12.31,"3,182,115",제 36 기,2013.01.01 ~ 2013.12.31,"-11,959,733",28,USD
336,781202,애머릿지,900100,2015,20160429000770,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 38 기,2015.01.01 ~ 2015.12.31,"-4,114,012",제 37 기,2014.01.01 ~ 2014.12.31,"3,182,115",제 36 기,2013.01.01 ~ 2013.12.31,"-12,945,219",30,USD
337,781202,애머릿지,900100,2015,20160429000770,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 38 기,2015.01.01 ~ 2015.12.31,"-4,114,012",제 37 기,2014.01.01 ~ 2014.12.31,"3,182,115",제 36 기,2013.01.01 ~ 2013.12.31,"-12,945,219",62,USD
361,781202,애머릿지,900100,2016,20170419000099,11011,CFS,재무제표,IS,손익계산서,매출액,제 39 기,2016.01.01 ~ 2016.12.31,"36,761,019",제 38 기,2015.01.01 ~ 2015.12.31,"53,519,782",제 37 기,2014.01.01 ~ 2014.12.31,"50,119,479",24,USD
362,781202,애머릿지,900100,2016,20170419000099,11011,CFS,재무제표,IS,손익계산서,영업이익,제 39 기,2016.01.01 ~ 2016.12.31,"-6,613,726",제 38 기,2015.01.01 ~ 2015.12.31,"-1,026,046",제 37 기,2014.01.01 ~ 2014.12.31,"778,385",26,USD
363,781202,애머릿지,900100,2016,20170419000099,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 39 기,2016.01.01 ~ 2016.12.31,"-14,026,844",제 38 기,2015.01.01 ~ 2015.12.31,"-4,114,012",제 37 기,2014.01.01 ~ 2014.12.31,"3,182,115",28,USD
364,781202,애머릿지,900100,2016,20170419000099,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 39 기,2016.01.01 ~ 2016.12.31,"-14,026,844",제 38 기,2015.01.01 ~ 2015.12.31,"-4,114,012",제 37 기,2014.01.01 ~ 2014.12.31,"3,182,115",30,USD
365,781202,애머릿지,900100,2016,20170419000099,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 39 기,2016.01.01 ~ 2016.12.31,"-14,026,844",제 38 기,2015.01.01 ~ 2015.12.31,"-4,114,012",제 37 기,2014.01.01 ~ 2014.12.31,"3,182,115",62,USD
385,781202,애머릿지,900100,2017,20180430000663,11011,CFS,재무제표,IS,손익계산서,매출액,제 40 기,2017.01.01 ~ 2017.12.31,"33,001,653",제 39 기,2016.01.01 ~ 2016.12.31,"36,761,019",제 38 기,2015.01.01 ~ 2015.12.31,"53,519,782",24,USD
386,781202,애머릿지,900100,2017,20180430000663,11011,CFS,재무제표,IS,손익계산서,영업이익,제 40 기,2017.01.01 ~ 2017.12.31,"-7,829,884",제 39 기,2016.01.01 ~ 2016.12.31,"-6,613,726",제 38 기,2015.01.01 ~ 2015.12.31,"-1,026,046",26,USD
387,781202,애머릿지,900100,2017,20180430000663,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 40 기,2017.01.01 ~ 2017.12.31,"-18,923,441",제 39 기,2016.01.01 ~ 2016.12.31,"-14,026,844",제 38 기,2015.01.01 ~ 2015.12.31,"-4,114,012",28,USD
388,781202,애머릿지,900100,2017,20180430000663,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 40 기,2017.01.01 ~ 2017.12.31,"-18,923,441",제 39 기,2016.01.01 ~ 2016.12.31,"-14,026,844",제 38 기,2015.01.01 ~ 2015.12.31,"-4,114,012",30,USD
389,781202,애머릿지,900100,2017,20180430000663,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 40 기,2017.01.01 ~ 2017.12.31,"-18,923,441",제 39 기,2016.01.01 ~ 2016.12.31,"-14,026,844",제 38 기,2015.01.01 ~ 2015.12.31,"-4,114,012",62,USD
413,781202,애머릿지,900100,2018,20210517001564,11011,CFS,재무제표,IS,손익계산서,매출액,제 41 기,2018.01.01 ~ 2018.12.31,"23,697,601",제 40 기,2017.01.01 ~ 2017.12.31,"33,001,653",제 39 기,2016.01.01 ~ 2016.12.31,"36,761,019",24,USD
414,781202,애머릿지,900100,2018,20210517001564,11011,CFS,재무제표,IS,손익계산서,영업이익,제 41 기,2018.01.01 ~ 2018.12.31,"-895,877",제 40 기,2017.01.01 ~ 2017.12.31,"-7,829,884",제 39 기,2016.01.01 ~ 2016.12.31,"-6,613,726",26,USD
415,781202,애머릿지,900100,2018,20210517001564,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 41 기,2018.01.01 ~ 2018.12.31,"-13,052,342",제 40 기,2017.01.01 ~ 2017.12.31,"-18,923,441",제 39 기,2016.01.01 ~ 2016.12.31,"-14,026,844",28,USD
416,781202,애머릿지,900100,2018,20210517001564,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 41 기,2018.01.01 ~ 2018.12.31,"-13,052,342",제 40 기,2017.01.01 ~ 2017.12.31,"-18,923,441",제 39 기,2016.01.01 ~ 2016.12.31,"-14,026,844",30,USD
417,781202,애머릿지,900100,2018,20210517001564,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 41 기,2018.01.01 ~ 2018.12.31,"-13,052,342",제 40 기,2017.01.01 ~ 2017.12.31,"-18,923,441",제 39 기,2016.01.01 ~ 2016.12.31,"-14,026,844",62,USD
441,781202,애머릿지,900100,2019,20210521000064,11011,CFS,재무제표,IS,손익계산서,매출액,제 42 기,2019.01.01 ~ 2019.12.31,"18,041,615",제 41 기,2018.01.01 ~ 2018.12.31,"23,697,601",제 40 기,2017.01.01 ~ 2017.12.31,"33,001,653",24,USD
442,781202,애머릿지,900100,2019,20210521000064,11011,CFS,재무제표,IS,손익계산서,영업이익,제 42 기,2019.01.01 ~ 2019.12.31,"874,493",제 41 기,2018.01.01 ~ 2018.12.31,"-895,877",제 40 기,2017.01.01 ~ 2017.12.31,"-7,829,884",26,USD
443,781202,애머릿지,900100,2019,20210521000064,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 42 기,2019.01.01 ~ 2019.12.31,"-70,876,119",제 41 기,2018.01.01 ~ 2018.12.31,"-13,052,342",제 40 기,2017.01.01 ~ 2017.12.31,"-18,923,441",28,USD
444,781202,애머릿지,900100,2019,20210521000064,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 42 기,2019.01.01 ~ 2019.12.31,"-70,876,119",제 41 기,2018.01.01 ~ 2018.12.31,"-13,052,342",제 40 기,2017.01.01 ~ 2017.12.31,"-18,923,441",30,USD
445,781202,애머릿지,900100,2019,20210521000064,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 42 기,2019.01.01 ~ 2019.12.31,"-70,876,119",제 41 기,2018.01.01 ~ 2018.12.31,"-13,052,342",제 40 기,2017.01.01 ~ 2017.12.31,"-18,923,441",62,USD
469,781202,애머릿지,900100,2020,20210527000430,11011,CFS,재무제표,IS,손익계산서,매출액,제 43 기,2020.01.01 ~ 2020.12.31,"24,761,431",제 42 기,2019.01.01 ~ 2019.12.31,"18,041,615",제 41 기,2018.01.01 ~ 2018.12.31,"23,697,601",24,USD
470,781202,애머릿지,900100,2020,20210527000430,11011,CFS,재무제표,IS,손익계산서,영업이익,제 43 기,2020.01.01 ~ 2020.12.31,"977,342",제 42 기,2019.01.01 ~ 2019.12.31,"874,493",제 41 기,2018.01.01 ~ 2018.12.31,"-895,877",26,USD
471,781202,애머릿지,900100,2020,20210527000430,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 43 기,2020.01.01 ~ 2020.12.31,"-9,273,001",제 42 기,2019.01.01 ~ 2019.12.31,"-70,876,119",제 41 기,2018.01.01 ~ 2018.12.31,"-13,052,342",28,USD
472,781202,애머릿지,900100,2020,20210527000430,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 43 기,2020.01.01 ~ 2020.12.31,"-9,273,001",제 42 기,2019.01.01 ~ 2019.12.31,"-70,876,119",제 41 기,2018.01.01 ~ 2018.12.31,"-13,052,342",30,USD
473,781202,애머릿지,900100,2020,20210527000430,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 43 기,2020.01.01 ~ 2020.12.31,"-9,273,001",제 42 기,2019.01.01 ~ 2019.12.31,"-70,876,119",제 41 기,2018.01.01 ~ 2018.12.31,"-13,052,342",62,USD
497,781202,애머릿지,900100,2021,20220420000483,11011,CFS,재무제표,IS,손익계산서,매출액,제 44 기,2021.01.01 ~ 2021.12.31,"40,634,156",제 43 기,2020.01.01 ~ 2020.12.31,"24,761,431",제 42 기,2019.01.01 ~ 2019.12.31,"18,041,615",24,USD
498,781202,애머릿지,900100,2021,20220420000483,11011,CFS,재무제표,IS,손익계산서,영업이익,제 44 기,2021.01.01 ~ 2021.12.31,"2,729,848",제 43 기,2020.01.01 ~ 2020.12.31,"977,342",제 42 기,2019.01.01 ~ 2019.12.31,"874,493",26,USD
499,781202,애머릿지,900100,2021,20220420000483,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",제 43 기,2020.01.01 ~ 2020.12.31,"-9,273,001",제 42 기,2019.01.01 ~ 2019.12.31,"-70,876,119",28,USD
500,781202,애머릿지,900100,2021,20220420000483,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",제 43 기,2020.01.01 ~ 2020.12.31,"-9,273,001",제 42 기,2019.01.01 ~ 2019.12.31,"-70,876,119",30,USD
501,781202,애머릿지,900100,2021,20220420000483,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",제 43 기,2020.01.01 ~ 2020.12.31,"-9,273,001",제 42 기,2019.01.01 ~ 2019.12.31,"-70,876,119",62,USD
525,781202,애머릿지,900100,2022,20230420000051,11011,CFS,재무제표,IS,손익계산서,매출액,제 45 기,2022.01.01 ~ 2022.12.31,"40,855,225",제 44 기,2021.01.01 ~ 2021.12.31,"40,634,156",제 43 기,2020.01.01 ~ 2020.12.31,"24,761,431",24,USD
526,781202,애머릿지,900100,2022,20230420000051,11011,CFS,재무제표,IS,손익계산서,영업이익,제 45 기,2022.01.01 ~ 2022.12.31,"1,780,836",제 44 기,2021.01.01 ~ 2021.12.31,"2,729,848",제 43 기,2020.01.01 ~ 2020.12.31,"977,342",26,USD
527,781202,애머릿지,900100,2022,20230420000051,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 45 기,2022.01.01 ~ 2022.12.31,"1,311,899",제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",제 43 기,2020.01.01 ~ 2020.12.31,"-9,273,001",28,USD
528,781202,애머릿지,900100,2022,20230420000051,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 45 기,2022.01.01 ~ 2022.12.31,"1,311,899",제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",제 43 기,2020.01.01 ~ 2020.12.31,"-9,273,001",30,USD
529,781202,애머릿지,900100,2022,20230420000051,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 45 기,2022.01.01 ~ 2022.12.31,"1,311,899",제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",제 43 기,2020.01.01 ~ 2020.12.31,"-9,273,001",62,USD
554,781202,애머릿지,900100,2023,20240422000306,11011,CFS,재무제표,IS,손익계산서,매출액,제 46 기,2023.01.01 ~ 2023.12.31,"26,554,598",제 45 기,2022.01.01 ~ 2022.12.31,"40,855,225",제 44 기,2021.01.01 ~ 2021.12.31,"40,634,156",24,USD
555,781202,애머릿지,900100,2023,20240422000306,11011,CFS,재무제표,IS,손익계산서,영업이익,제 46 기,2023.01.01 ~ 2023.12.31,"-7,137,372",제 45 기,2022.01.01 ~ 2022.12.31,"1,780,836",제 44 기,2021.01.01 ~ 2021.12.31,"2,729,848",26,USD
556,781202,애머릿지,900100,2023,20240422000306,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 46 기,2023.01.01 ~ 2023.12.31,"-28,115,591",제 45 기,2022.01.01 ~ 2022.12.31,"1,311,899",제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",28,USD
557,781202,애머릿지,900100,2023,20240422000306,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 46 기,2023.01.01 ~ 2023.12.31,"-28,115,591",제 45 기,2022.01.01 ~ 2022.12.31,"1,311,899",제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",30,USD
558,781202,애머릿지,900100,2023,20240422000306,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 46 기,2023.01.01 ~ 2023.12.31,"-28,115,591",제 45 기,2022.01.01 ~ 2022.12.31,"1,311,899",제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",62,USD
559,781202,애머릿지,900100,2023,20240422000306,11011,CFS,재무제표,IS,손익계산서,총포괄손익,제 46 기,2023.01.01 ~ 2023.12.31,"-28,115,591",제 45 기,2022.01.01 ~ 2022.12.31,"1,311,899",제 44 기,2021.01.01 ~ 2021.12.31,"1,472,781",64,USD
1879,956028,엑세스바이오,950130,2017,20180420000307,11011,CFS,재무제표,IS,손익계산서,매출액,제 16 기,2017.01.01 ~ 2017.12.31,"24,347,218",제 15 기,2016.01.01 ~ 2016.12.31,"25,646,646",제 14 기,2015.01.01 ~ 2015.12.31,"30,719,273",24,USD
1880,956028,엑세스바이오,950130,2017,20180420000307,11011,CFS,재무제표,IS,손익계산서,영업이익,제 16 기,2017.01.01 ~ 2017.12.31,"120,381",제 15 기,2016.01.01 ~ 2016.12.31,"1,375,204",제 14 기,2015.01.01 ~ 2015.12.31,"1,712,631",26,USD
1881,956028,엑세스바이오,950130,2017,20180420000307,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 16 기,2017.01.01 ~ 2017.12.31,"-2,821,929",제 15 기,2016.01.01 ~ 2016.12.31,"2,061,299",제 14 기,2015.01.01 ~ 2015.12.31,"2,977,405",28,USD
1882,956028,엑세스바이오,950130,2017,20180420000307,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 16 기,2017.01.01 ~ 2017.12.31,"-1,629,679",제 15 기,2016.01.01 ~ 2016.12.31,"1,119,136",제 14 기,2015.01.01 ~ 2015.12.31,"1,942,591",30,USD
1883,956028,엑세스바이오,950130,2017,20180420000307,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 16 기,2017.01.01 ~ 2017.12.31,"-1,629,679",제 15 기,2016.01.01 ~ 2016.12.31,"1,119,136",제 14 기,2015.01.01 ~ 2015.12.31,"1,942,591",62,USD
1905,956028,엑세스바이오,950130,2016,20180108000301,11011,CFS,재무제표,IS,손익계산서,매출액,제 15 기,2016.01.01 ~ 2016.12.31,"25,646,646",제 14 기,2015.01.01 ~ 2015.12.31,"30,719,273",제 13 기,2014.01.01 ~ 2014.12.31,"30,751,006",24,USD
1906,956028,엑세스바이오,950130,2016,20180108000301,11011,CFS,재무제표,IS,손익계산서,영업이익,제 15 기,2016.01.01 ~ 2016.12.31,"1,375,204",제 14 기,2015.01.01 ~ 2015.12.31,"1,712,631",제 13 기,2014.01.01 ~ 2014.12.31,"3,867,638",26,USD
1907,956028,엑세스바이오,950130,2016,20180108000301,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 15 기,2016.01.01 ~ 2016.12.31,"2,061,299",제 14 기,2015.01.01 ~ 2015.12.31,"2,977,405",제 13 기,2014.01.01 ~ 2014.12.31,"4,002,858",28,USD
1908,956028,엑세스바이오,950130,2016,20180108000301,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 15 기,2016.01.01 ~ 2016.12.31,"1,119,136",제 14 기,2015.01.01 ~ 2015.12.31,"1,942,591",제 13 기,2014.01.01 ~ 2014.12.31,"3,297,497",30,USD
1909,956028,엑세스바이오,950130,2016,20180108000301,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 15 기,2016.01.01 ~ 2016.12.31,"1,119,136",제 14 기,2015.01.01 ~ 2015.12.31,"1,942,591",제 13 기,2014.01.01 ~ 2014.12.31,"3,297,497",62,USD
1931,956028,엑세스바이오,950130,2015,20160422000046,11011,CFS,재무제표,IS,손익계산서,매출액,제 14 기,2015.01.01 ~ 2015.12.31,"30,719,273",제 13 기,2014.01.01 ~ 2014.12.31,"30,751,006",제 12 기,2013.01.01 ~ 2013.12.31,"41,859,412",24,USD
1932,956028,엑세스바이오,950130,2015,20160422000046,11011,CFS,재무제표,IS,손익계산서,영업이익,제 14 기,2015.01.01 ~ 2015.12.31,"1,712,631",제 13 기,2014.01.01 ~ 2014.12.31,"3,867,638",제 12 기,2013.01.01 ~ 2013.12.31,"10,835,522",26,USD
1933,956028,엑세스바이오,950130,2015,20160422000046,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 14 기,2015.01.01 ~ 2015.12.31,"2,977,405",제 13 기,2014.01.01 ~ 2014.12.31,"4,002,858",제 12 기,2013.01.01 ~ 2013.12.31,"11,472,071",28,USD
1934,956028,엑세스바이오,950130,2015,20160422000046,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 14 기,2015.01.01 ~ 2015.12.31,"1,942,591",제 13 기,2014.01.01 ~ 2014.12.31,"3,297,497",제 12 기,2013.01.01 ~ 2013.12.31,"7,544,826",30,USD
1935,956028,엑세스바이오,950130,2015,20160422000046,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 14 기,2015.01.01 ~ 2015.12.31,"1,942,591",제 13 기,2014.01.01 ~ 2014.12.31,"3,297,497",제 12 기,2013.01.01 ~ 2013.12.31,"7,544,826",62,USD
1959,956028,엑세스바이오,950130,2020,20210316000210,11011,CFS,재무제표,IS,손익계산서,매출액,제 19 기,2020.01.01 ~ 2020.12.31,"92,215,510",제 18 기,2019.01.01 ~ 2019.12.31,"32,067,422",제 17 기,2018.01.01 ~ 2018.12.31,"34,158,734",24,USD
1960,956028,엑세스바이오,950130,2020,20210316000210,11011,CFS,재무제표,IS,손익계산서,영업이익,제 19 기,2020.01.01 ~ 2020.12.31,"58,701,187",제 18 기,2019.01.01 ~ 2019.12.31,"-2,688,741",제 17 기,2018.01.01 ~ 2018.12.31,"870,002",26,USD
1961,956028,엑세스바이오,950130,2020,20210316000210,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 19 기,2020.01.01 ~ 2020.12.31,"55,976,701",제 18 기,2019.01.01 ~ 2019.12.31,"-7,141,671",제 17 기,2018.01.01 ~ 2018.12.31,"956,988",28,USD
1962,956028,엑세스바이오,950130,2020,20210316000210,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 19 기,2020.01.01 ~ 2020.12.31,"43,561,926",제 18 기,2019.01.01 ~ 2019.12.31,"-6,263,868",제 17 기,2018.01.01 ~ 2018.12.31,"735,372",30,USD
1963,956028,엑세스바이오,950130,2020,20210316000210,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 19 기,2020.01.01 ~ 2020.12.31,"43,561,926",제 18 기,2019.01.01 ~ 2019.12.31,"-6,263,868",제 17 기,2018.01.01 ~ 2018.12.31,"735,372",62,USD
1987,956028,엑세스바이오,950130,2018,20190430001200,11011,CFS,재무제표,IS,손익계산서,매출액,제 17 기,2018.01.01 ~ 2018.12.31,"34,158,734",제 16 기,2017.01.01 ~ 2017.12.31,"24,347,218",제 15 기,2016.01.01 ~ 2016.12.31,"25,646,646",24,USD
1988,956028,엑세스바이오,950130,2018,20190430001200,11011,CFS,재무제표,IS,손익계산서,영업이익,제 17 기,2018.01.01 ~ 2018.12.31,"870,002",제 16 기,2017.01.01 ~ 2017.12.31,"120,381",제 15 기,2016.01.01 ~ 2016.12.31,"1,375,204",26,USD
1989,956028,엑세스바이오,950130,2018,20190430001200,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 17 기,2018.01.01 ~ 2018.12.31,"956,988",제 16 기,2017.01.01 ~ 2017.12.31,"-2,821,929",제 15 기,2016.01.01 ~ 2016.12.31,"2,061,299",28,USD
1990,956028,엑세스바이오,950130,2018,20190430001200,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 17 기,2018.01.01 ~ 2018.12.31,"735,372",제 16 기,2017.01.01 ~ 2017.12.31,"-1,629,679",제 15 기,2016.01.01 ~ 2016.12.31,"1,119,136",30,USD
1991,956028,엑세스바이오,950130,2018,20190430001200,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 17 기,2018.01.01 ~ 2018.12.31,"735,372",제 16 기,2017.01.01 ~ 2017.12.31,"-1,629,679",제 15 기,2016.01.01 ~ 2016.12.31,"1,119,136",62,USD
2015,956028,엑세스바이오,950130,2019,20200424000043,11011,CFS,재무제표,IS,손익계산서,매출액,제 18 기,2019.01.01 ~ 2019.12.31,"32,067,422",제 17 기,2018.01.01 ~ 2018.12.31,"34,158,734",제 16 기,2017.01.01 ~ 2017.12.31,"24,347,218",24,USD
2016,956028,엑세스바이오,950130,2019,20200424000043,11011,CFS,재무제표,IS,손익계산서,영업이익,제 18 기,2019.01.01 ~ 2019.12.31,"-2,688,741",제 17 기,2018.01.01 ~ 2018.12.31,"870,002",제 16 기,2017.01.01 ~ 2017.12.31,"120,381",26,USD
2017,956028,엑세스바이오,950130,2019,20200424000043,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 18 기,2019.01.01 ~ 2019.12.31,"-7,141,671",제 17 기,2018.01.01 ~ 2018.12.31,"956,988",제 16 기,2017.01.01 ~ 2017.12.31,"-2,821,929",28,USD
2018,956028,엑세스바이오,950130,2019,20200424000043,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 18 기,2019.01.01 ~ 2019.12.31,"-6,263,868",제 17 기,2018.01.01 ~ 2018.12.31,"735,372",제 16 기,2017.01.01 ~ 2017.12.31,"-1,629,679",30,USD
2019,956028,엑세스바이오,950130,2019,20200424000043,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 18 기,2019.01.01 ~ 2019.12.31,"-6,263,868",제 17 기,2018.01.01 ~ 2018.12.31,"735,372",제 16 기,2017.01.01 ~ 2017.12.31,"-1,629,679",62,USD
2044,956028,엑세스바이오,950130,2023,20240319000134,11011,CFS,재무제표,IS,손익계산서,매출액,제 22 기,2023.01.01 ~ 2023.12.31,"255,766,548",제 21 기,2022.01.01 ~ 2022.12.31,"763,370,040",제 20 기,2021.01.01 ~ 2021.12.31,"417,301,334",24,USD
2045,956028,엑세스바이오,950130,2023,20240319000134,11011,CFS,재무제표,IS,손익계산서,영업이익,제 22 기,2023.01.01 ~ 2023.12.31,"27,946,053",제 21 기,2022.01.01 ~ 2022.12.31,"336,120,690",제 20 기,2021.01.01 ~ 2021.12.31,"218,551,849",26,USD
2046,956028,엑세스바이오,950130,2023,20240319000134,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 22 기,2023.01.01 ~ 2023.12.31,"3,679,920",제 21 기,2022.01.01 ~ 2022.12.31,"332,635,339",제 20 기,2021.01.01 ~ 2021.12.31,"217,381,485",28,USD
2047,956028,엑세스바이오,950130,2023,20240319000134,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 22 기,2023.01.01 ~ 2023.12.31,"4,615,361",제 21 기,2022.01.01 ~ 2022.12.31,"247,502,675",제 20 기,2021.01.01 ~ 2021.12.31,"160,493,911",30,USD
2048,956028,엑세스바이오,950130,2023,20240319000134,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 22 기,2023.01.01 ~ 2023.12.31,"4,615,361",제 21 기,2022.01.01 ~ 2022.12.31,"247,502,675",제 20 기,2021.01.01 ~ 2021.12.31,"160,493,911",62,USD
2049,956028,엑세스바이오,950130,2023,20240319000134,11011,CFS,재무제표,IS,손익계산서,총포괄손익,제 22 기,2023.01.01 ~ 2023.12.31,"4,444,249",제 21 기,2022.01.01 ~ 2022.12.31,"247,423,012",제 20 기,2021.01.01 ~ 2021.12.31,"160,663,239",64,USD
2073,956028,엑세스바이오,950130,2021,20220322000596,11011,CFS,재무제표,IS,손익계산서,매출액,제 20 기,2021.01.01 ~ 2021.12.31,"417,301,334",제 19 기,2020.01.01 ~ 2020.12.31,"92,215,510",제 18 기,2019.01.01 ~ 2019.12.31,"32,067,422",24,USD
2074,956028,엑세스바이오,950130,2021,20220322000596,11011,CFS,재무제표,IS,손익계산서,영업이익,제 20 기,2021.01.01 ~ 2021.12.31,"218,551,849",제 19 기,2020.01.01 ~ 2020.12.31,"58,701,187",제 18 기,2019.01.01 ~ 2019.12.31,"-2,688,741",26,USD
2075,956028,엑세스바이오,950130,2021,20220322000596,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 20 기,2021.01.01 ~ 2021.12.31,"217,381,485",제 19 기,2020.01.01 ~ 2020.12.31,"55,976,701",제 18 기,2019.01.01 ~ 2019.12.31,"-7,141,671",28,USD
2076,956028,엑세스바이오,950130,2021,20220322000596,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 20 기,2021.01.01 ~ 2021.12.31,"160,493,911",제 19 기,2020.01.01 ~ 2020.12.31,"43,561,926",제 18 기,2019.01.01 ~ 2019.12.31,"-6,263,868",30,USD
2077,956028,엑세스바이오,950130,2021,20220322000596,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 20 기,2021.01.01 ~ 2021.12.31,"160,493,911",제 19 기,2020.01.01 ~ 2020.12.31,"43,561,926",제 18 기,2019.01.01 ~ 2019.12.31,"-6,263,868",62,USD
2101,956028,엑세스바이오,950130,2022,20230320000463,11011,CFS,재무제표,IS,손익계산서,매출액,제 21 기,2022.01.01 ~ 2022.12.31,"763,370,040",제 20 기,2021.01.01 ~ 2021.12.31,"417,301,334",제 19 기,2020.01.01 ~ 2020.12.31,"92,215,510",24,USD
2102,956028,엑세스바이오,950130,2022,20230320000463,11011,CFS,재무제표,IS,손익계산서,영업이익,제 21 기,2022.01.01 ~ 2022.12.31,"336,120,690",제 20 기,2021.01.01 ~ 2021.12.31,"218,551,849",제 19 기,2020.01.01 ~ 2020.12.31,"58,701,187",26,USD
2103,956028,엑세스바이오,950130,2022,20230320000463,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 21 기,2022.01.01 ~ 2022.12.31,"332,635,339",제 20 기,2021.01.01 ~ 2021.12.31,"217,381,485",제 19 기,2020.01.01 ~ 2020.12.31,"55,976,701",28,USD
2104,956028,엑세스바이오,950130,2022,20230320000463,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 21 기,2022.01.01 ~ 2022.12.31,"247,502,675",제 20 기,2021.01.01 ~ 2021.12.31,"160,493,911",제 19 기,2020.01.01 ~ 2020.12.31,"43,561,926",30,USD
2105,956028,엑세스바이오,950130,2022,20230320000463,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 21 기,2022.01.01 ~ 2022.12.31,"247,502,675",제 20 기,2021.01.01 ~ 2021.12.31,"160,493,911",제 19 기,2020.01.01 ~ 2020.12.31,"43,561,926",62,USD
2129,1165739,잉글우드랩,950140,2017,20180430001776,11011,CFS,재무제표,IS,손익계산서,매출액,제 3 기,2017.01.01 ~ 2017.12.31,"69,149,843",제 2 기,2016.01.01 ~ 2016.12.31,"68,065,955",제 1 기,2015.08.20 ~ 2015.12.31,-,24,USD
2130,1165739,잉글우드랩,950140,2017,20180430001776,11011,CFS,재무제표,IS,손익계산서,영업이익,제 3 기,2017.01.01 ~ 2017.12.31,"-3,982,045",제 2 기,2016.01.01 ~ 2016.12.31,"6,272,677",제 1 기,2015.08.20 ~ 2015.12.31,-,26,USD
2131,1165739,잉글우드랩,950140,2017,20180430001776,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 3 기,2017.01.01 ~ 2017.12.31,"-15,026,709",제 2 기,2016.01.01 ~ 2016.12.31,"2,069,300",제 1 기,2015.08.20 ~ 2015.12.31,-,28,USD
2132,1165739,잉글우드랩,950140,2017,20180430001776,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 3 기,2017.01.01 ~ 2017.12.31,"-13,864,646",제 2 기,2016.01.01 ~ 2016.12.31,"-83,712",제 1 기,2015.08.20 ~ 2015.12.31,-,30,USD
2133,1165739,잉글우드랩,950140,2017,20180430001776,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 3 기,2017.01.01 ~ 2017.12.31,"-13,864,646",제 2 기,2016.01.01 ~ 2016.12.31,"-83,712",제 1 기,2015.08.20 ~ 2015.12.31,-,62,USD
2152,1165739,잉글우드랩,950140,2016,20170428000634,11011,CFS,재무제표,IS,손익계산서,매출액,제 2 기,2016.01.01 ~ 2016.12.31,-,제 1 기,2015.08.20 ~ 2015.12.31,-,,,-,24,USD
2153,1165739,잉글우드랩,950140,2016,20170428000634,11011,CFS,재무제표,IS,손익계산서,영업이익,제 2 기,2016.01.01 ~ 2016.12.31,"-130,220",제 1 기,2015.08.20 ~ 2015.12.31,"-2,030",,,-,26,USD
2154,1165739,잉글우드랩,950140,2016,20170428000634,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 2 기,2016.01.01 ~ 2016.12.31,"2,108,507",제 1 기,2015.08.20 ~ 2015.12.31,"597,970",,,-,28,USD
2155,1165739,잉글우드랩,950140,2016,20170428000634,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 2 기,2016.01.01 ~ 2016.12.31,"-359,554",제 1 기,2015.08.20 ~ 2015.12.31,"342,069",,,-,30,USD
2156,1165739,잉글우드랩,950140,2016,20170428000634,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 2 기,2016.01.01 ~ 2016.12.31,"-359,554",제 1 기,2015.08.20 ~ 2015.12.31,"342,069",,,-,62,USD
2180,1165739,잉글우드랩,950140,2018,20190329003235,11011,CFS,재무제표,IS,손익계산서,매출액,제 4 기,2018.01.01 ~ 2018.12.31,"91,377,187",제 3 기,2017.01.01 ~ 2017.12.31,"69,149,843",제 2 기,2016.01.01 ~ 2016.12.31,"68,065,955",24,USD
2181,1165739,잉글우드랩,950140,2018,20190329003235,11011,CFS,재무제표,IS,손익계산서,영업이익,제 4 기,2018.01.01 ~ 2018.12.31,"3,641,676",제 3 기,2017.01.01 ~ 2017.12.31,"-3,982,045",제 2 기,2016.01.01 ~ 2016.12.31,"6,272,677",26,USD
2182,1165739,잉글우드랩,950140,2018,20190329003235,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 4 기,2018.01.01 ~ 2018.12.31,"-2,953,784",제 3 기,2017.01.01 ~ 2017.12.31,"-15,026,709",제 2 기,2016.01.01 ~ 2016.12.31,"2,069,300",28,USD
2183,1165739,잉글우드랩,950140,2018,20190329003235,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 4 기,2018.01.01 ~ 2018.12.31,"-3,714,588",제 3 기,2017.01.01 ~ 2017.12.31,"-13,864,646",제 2 기,2016.01.01 ~ 2016.12.31,"-83,712",30,USD
2184,1165739,잉글우드랩,950140,2018,20190329003235,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 4 기,2018.01.01 ~ 2018.12.31,"-3,714,588",제 3 기,2017.01.01 ~ 2017.12.31,"-13,864,646",제 2 기,2016.01.01 ~ 2016.12.31,"-83,712",62,USD
2208,1165739,잉글우드랩,950140,2019,20200330002322,11011,CFS,재무제표,IS,손익계산서,매출액,제 5 기,2019.01.01 ~ 2019.12.31,"100,093,274",제 4 기,2018.01.01 ~ 2018.12.31,"91,377,187",제 3 기,2017.01.01 ~ 2017.12.31,"69,149,843",24,USD
2209,1165739,잉글우드랩,950140,2019,20200330002322,11011,CFS,재무제표,IS,손익계산서,영업이익,제 5 기,2019.01.01 ~ 2019.12.31,"8,189,266",제 4 기,2018.01.01 ~ 2018.12.31,"3,641,676",제 3 기,2017.01.01 ~ 2017.12.31,"-3,982,045",26,USD
2210,1165739,잉글우드랩,950140,2019,20200330002322,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 5 기,2019.01.01 ~ 2019.12.31,"5,373,682",제 4 기,2018.01.01 ~ 2018.12.31,"-2,953,784",제 3 기,2017.01.01 ~ 2017.12.31,"-15,026,709",28,USD
2211,1165739,잉글우드랩,950140,2019,20200330002322,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 5 기,2019.01.01 ~ 2019.12.31,"2,480,110",제 4 기,2018.01.01 ~ 2018.12.31,"-3,714,588",제 3 기,2017.01.01 ~ 2017.12.31,"-13,864,646",30,USD
2212,1165739,잉글우드랩,950140,2019,20200330002322,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 5 기,2019.01.01 ~ 2019.12.31,"2,480,110",제 4 기,2018.01.01 ~ 2018.12.31,"-3,714,588",제 3 기,2017.01.01 ~ 2017.12.31,"-13,864,646",62,USD
2236,1165739,잉글우드랩,950140,2020,20210317001183,11011,CFS,재무제표,IS,손익계산서,매출액,제 6 기,2020.01.01 ~ 2020.12.31,"94,231,229",제 5 기,2019.01.01 ~ 2019.12.31,"100,093,274",제 4 기,2018.01.01 ~ 2018.12.31,"91,377,187",24,USD
2237,1165739,잉글우드랩,950140,2020,20210317001183,11011,CFS,재무제표,IS,손익계산서,영업이익,제 6 기,2020.01.01 ~ 2020.12.31,"5,264,969",제 5 기,2019.01.01 ~ 2019.12.31,"8,189,266",제 4 기,2018.01.01 ~ 2018.12.31,"3,641,676",26,USD
2238,1165739,잉글우드랩,950140,2020,20210317001183,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 6 기,2020.01.01 ~ 2020.12.31,"6,412,543",제 5 기,2019.01.01 ~ 2019.12.31,"5,373,682",제 4 기,2018.01.01 ~ 2018.12.31,"-2,953,784",28,USD
2239,1165739,잉글우드랩,950140,2020,20210317001183,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 6 기,2020.01.01 ~ 2020.12.31,"4,732,034",제 5 기,2019.01.01 ~ 2019.12.31,"2,480,110",제 4 기,2018.01.01 ~ 2018.12.31,"-3,714,588",30,USD
2240,1165739,잉글우드랩,950140,2020,20210317001183,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 6 기,2020.01.01 ~ 2020.12.31,"4,732,034",제 5 기,2019.01.01 ~ 2019.12.31,"2,480,110",제 4 기,2018.01.01 ~ 2018.12.31,"-3,714,588",62,USD
2264,1165739,잉글우드랩,950140,2021,20220316001223,11011,CFS,재무제표,IS,손익계산서,매출액,제 7 기,2021.01.01 ~ 2021.12.31,"96,928,544",제 6 기,2020.01.01 ~ 2020.12.31,"94,231,229",제 5 기,2019.01.01 ~ 2019.12.31,"100,093,274",24,USD
2265,1165739,잉글우드랩,950140,2021,20220316001223,11011,CFS,재무제표,IS,손익계산서,영업이익,제 7 기,2021.01.01 ~ 2021.12.31,"11,244,092",제 6 기,2020.01.01 ~ 2020.12.31,"5,264,969",제 5 기,2019.01.01 ~ 2019.12.31,"8,189,266",26,USD
2266,1165739,잉글우드랩,950140,2021,20220316001223,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 7 기,2021.01.01 ~ 2021.12.31,"12,687,202",제 6 기,2020.01.01 ~ 2020.12.31,"6,412,543",제 5 기,2019.01.01 ~ 2019.12.31,"5,373,682",28,USD
2267,1165739,잉글우드랩,950140,2021,20220316001223,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 7 기,2021.01.01 ~ 2021.12.31,"11,002,008",제 6 기,2020.01.01 ~ 2020.12.31,"4,732,034",제 5 기,2019.01.01 ~ 2019.12.31,"2,480,110",30,USD
2268,1165739,잉글우드랩,950140,2021,20220316001223,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 7 기,2021.01.01 ~ 2021.12.31,"11,002,008",제 6 기,2020.01.01 ~ 2020.12.31,"4,732,034",제 5 기,2019.01.01 ~ 2019.12.31,"2,480,110",62,USD
2292,1165739,잉글우드랩,950140,2022,20230315001347,11011,CFS,재무제표,IS,손익계산서,매출액,제 8 기,2022.01.01 ~ 2022.12.31,"85,223,682",제 7 기,2021.01.01 ~ 2021.12.31,"96,928,544",제 6 기,2020.01.01 ~ 2020.12.31,"94,231,229",24,USD
2293,1165739,잉글우드랩,950140,2022,20230315001347,11011,CFS,재무제표,IS,손익계산서,영업이익,제 8 기,2022.01.01 ~ 2022.12.31,"3,644,938",제 7 기,2021.01.01 ~ 2021.12.31,"11,244,092",제 6 기,2020.01.01 ~ 2020.12.31,"5,264,969",26,USD
2294,1165739,잉글우드랩,950140,2022,20230315001347,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 8 기,2022.01.01 ~ 2022.12.31,"5,602,871",제 7 기,2021.01.01 ~ 2021.12.31,"12,687,202",제 6 기,2020.01.01 ~ 2020.12.31,"6,412,543",28,USD
2295,1165739,잉글우드랩,950140,2022,20230315001347,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 8 기,2022.01.01 ~ 2022.12.31,"5,213,015",제 7 기,2021.01.01 ~ 2021.12.31,"11,002,008",제 6 기,2020.01.01 ~ 2020.12.31,"4,732,034",30,USD
2296,1165739,잉글우드랩,950140,2022,20230315001347,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 8 기,2022.01.01 ~ 2022.12.31,"5,213,015",제 7 기,2021.01.01 ~ 2021.12.31,"11,002,008",제 6 기,2020.01.01 ~ 2020.12.31,"4,732,034",62,USD
2321,1165739,잉글우드랩,950140,2023,20240321001486,11011,CFS,재무제표,IS,손익계산서,매출액,제 9 기,2023.01.01 ~ 2023.12.31,"81,323,710",제 8 기,2022.01.01 ~ 2022.12.31,"85,223,682",제 7 기,2021.01.01 ~ 2021.12.31,"96,928,544",24,USD
2322,1165739,잉글우드랩,950140,2023,20240321001486,11011,CFS,재무제표,IS,손익계산서,영업이익,제 9 기,2023.01.01 ~ 2023.12.31,"3,499,827",제 8 기,2022.01.01 ~ 2022.12.31,"3,644,938",제 7 기,2021.01.01 ~ 2021.12.31,"11,244,092",26,USD
2323,1165739,잉글우드랩,950140,2023,20240321001486,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 9 기,2023.01.01 ~ 2023.12.31,"9,975,273",제 8 기,2022.01.01 ~ 2022.12.31,"5,602,871",제 7 기,2021.01.01 ~ 2021.12.31,"12,687,202",28,USD
2324,1165739,잉글우드랩,950140,2023,20240321001486,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 9 기,2023.01.01 ~ 2023.12.31,"9,454,868",제 8 기,2022.01.01 ~ 2022.12.31,"5,213,015",제 7 기,2021.01.01 ~ 2021.12.31,"11,002,008",30,USD
2325,1165739,잉글우드랩,950140,2023,20240321001486,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 9 기,2023.01.01 ~ 2023.12.31,"9,454,868",제 8 기,2022.01.01 ~ 2022.12.31,"5,213,015",제 7 기,2021.01.01 ~ 2021.12.31,"11,002,008",62,USD
2326,1165739,잉글우드랩,950140,2023,20240321001486,11011,CFS,재무제표,IS,손익계산서,총포괄손익,제 9 기,2023.01.01 ~ 2023.12.31,"9,454,868",제 8 기,2022.01.01 ~ 2022.12.31,"5,213,015",제 7 기,2021.01.01 ~ 2021.12.31,"11,002,008",64,USD
2336,1245062,코오롱티슈진,950160,2017,20210121000029,11011,CFS,재무제표,IS,손익계산서,매출액,제 19 기,2017.01.01 ~ 2017.12.31,"2,822,887",제 18 기,2016.01.01 ~ 2016.12.31,"11,455,989",제 17 기,2015.01.01 ~ 2015.12.31,"274,327",24,USD
2337,1245062,코오롱티슈진,950160,2017,20210121000029,11011,CFS,재무제표,IS,손익계산서,영업이익,제 19 기,2017.01.01 ~ 2017.12.31,"-36,029,293",제 18 기,2016.01.01 ~ 2016.12.31,"-3,383,998",제 17 기,2015.01.01 ~ 2015.12.31,"-7,449,949",26,USD
2338,1245062,코오롱티슈진,950160,2017,20210121000029,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 19 기,2017.01.01 ~ 2017.12.31,"-36,859,179",제 18 기,2016.01.01 ~ 2016.12.31,"-3,855,767",제 17 기,2015.01.01 ~ 2015.12.31,"-7,591,267",28,USD
2339,1245062,코오롱티슈진,950160,2017,20210121000029,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 19 기,2017.01.01 ~ 2017.12.31,"-40,176,191",제 18 기,2016.01.01 ~ 2016.12.31,"-2,259,777",제 17 기,2015.01.01 ~ 2015.12.31,"-7,591,267",30,USD
2340,1245062,코오롱티슈진,950160,2017,20210121000029,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 19 기,2017.01.01 ~ 2017.12.31,"-40,176,191",제 18 기,2016.01.01 ~ 2016.12.31,"-2,259,777",제 17 기,2015.01.01 ~ 2015.12.31,"-7,591,267",62,USD
2350,1245062,코오롱티슈진,950160,2018,20210121000034,11011,CFS,재무제표,IS,손익계산서,매출액,제 20 기,2018.01.01 ~ 2018.12.31,"3,440,200",제 19 기,2017.01.01 ~ 2017.12.31,"2,822,887",제 18 기,2016.01.01 ~ 2016.12.31,"11,455,989",24,USD
2351,1245062,코오롱티슈진,950160,2018,20210121000034,11011,CFS,재무제표,IS,손익계산서,영업이익,제 20 기,2018.01.01 ~ 2018.12.31,"-29,937,807",제 19 기,2017.01.01 ~ 2017.12.31,"-36,029,293",제 18 기,2016.01.01 ~ 2016.12.31,"-3,383,998",26,USD
2352,1245062,코오롱티슈진,950160,2018,20210121000034,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 20 기,2018.01.01 ~ 2018.12.31,"-29,294,662",제 19 기,2017.01.01 ~ 2017.12.31,"-36,859,179",제 18 기,2016.01.01 ~ 2016.12.31,"-3,855,767",28,USD
2353,1245062,코오롱티슈진,950160,2018,20210121000034,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 20 기,2018.01.01 ~ 2018.12.31,"-29,324,152",제 19 기,2017.01.01 ~ 2017.12.31,"-40,176,191",제 18 기,2016.01.01 ~ 2016.12.31,"-2,259,777",30,USD
2354,1245062,코오롱티슈진,950160,2018,20210121000034,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 20 기,2018.01.01 ~ 2018.12.31,"-29,324,152",제 19 기,2017.01.01 ~ 2017.12.31,"-40,176,191",제 18 기,2016.01.01 ~ 2016.12.31,"-2,259,777",62,USD
2364,1245062,코오롱티슈진,950160,2019,20210121000197,11011,CFS,재무제표,IS,손익계산서,매출액,제 21 기,2019.01.01 ~ 2019.12.31,"2,619,408",제 20 기,2018.01.01 ~ 2018.12.31,"3,440,200",제 19 기,2017.01.01 ~ 2017.12.31,"2,822,887",24,USD
2365,1245062,코오롱티슈진,950160,2019,20210121000197,11011,CFS,재무제표,IS,손익계산서,영업이익,제 21 기,2019.01.01 ~ 2019.12.31,"-38,192,414",제 20 기,2018.01.01 ~ 2018.12.31,"-29,937,807",제 19 기,2017.01.01 ~ 2017.12.31,"-36,029,293",26,USD
2366,1245062,코오롱티슈진,950160,2019,20210121000197,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 21 기,2019.01.01 ~ 2019.12.31,"-42,223,863",제 20 기,2018.01.01 ~ 2018.12.31,"-29,294,662",제 19 기,2017.01.01 ~ 2017.12.31,"-36,859,179",28,USD
2367,1245062,코오롱티슈진,950160,2019,20210121000197,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 21 기,2019.01.01 ~ 2019.12.31,"-42,268,273",제 20 기,2018.01.01 ~ 2018.12.31,"-29,324,152",제 19 기,2017.01.01 ~ 2017.12.31,"-40,176,191",30,USD
2368,1245062,코오롱티슈진,950160,2019,20210121000197,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 21 기,2019.01.01 ~ 2019.12.31,"-42,268,273",제 20 기,2018.01.01 ~ 2018.12.31,"-29,324,152",제 19 기,2017.01.01 ~ 2017.12.31,"-40,176,191",62,USD
2378,1245062,코오롱티슈진,950160,2020,20210324000788,11011,CFS,재무제표,IS,손익계산서,매출액,제 22 기,2020.01.01 ~ 2020.12.31,"3,013,298",제 21 기,2019.01.01 ~ 2019.12.31,"2,603,554",제 20 기,2018.01.01 ~ 2018.12.31,"3,440,200",24,USD
2379,1245062,코오롱티슈진,950160,2020,20210324000788,11011,CFS,재무제표,IS,손익계산서,영업이익,제 22 기,2020.01.01 ~ 2020.12.31,"-35,215,717",제 21 기,2019.01.01 ~ 2019.12.31,"-38,757,201",제 20 기,2018.01.01 ~ 2018.12.31,"-29,937,807",26,USD
2380,1245062,코오롱티슈진,950160,2020,20210324000788,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 22 기,2020.01.01 ~ 2020.12.31,"-35,307,618",제 21 기,2019.01.01 ~ 2019.12.31,"-42,840,351",제 20 기,2018.01.01 ~ 2018.12.31,"-29,294,662",28,USD
2381,1245062,코오롱티슈진,950160,2020,20210324000788,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 22 기,2020.01.01 ~ 2020.12.31,"-35,412,429",제 21 기,2019.01.01 ~ 2019.12.31,"-42,884,761",제 20 기,2018.01.01 ~ 2018.12.31,"-29,324,152",30,USD
2382,1245062,코오롱티슈진,950160,2020,20210324000788,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 22 기,2020.01.01 ~ 2020.12.31,"-35,412,429",제 21 기,2019.01.01 ~ 2019.12.31,"-42,884,761",제 20 기,2018.01.01 ~ 2018.12.31,"-29,324,152",62,USD
2392,1245062,코오롱티슈진,950160,2021,20220321001506,11011,CFS,재무제표,IS,손익계산서,매출액,제 23 기,2021.01.01 ~ 2021.12.31,"3,497,973",제 22 기,2020.01.01 ~ 2020.12.31,"3,013,298",제 21 기,2019.01.01 ~ 2019.12.31,"2,603,554",24,USD
2393,1245062,코오롱티슈진,950160,2021,20220321001506,11011,CFS,재무제표,IS,손익계산서,영업이익,제 23 기,2021.01.01 ~ 2021.12.31,"-40,984,035",제 22 기,2020.01.01 ~ 2020.12.31,"-35,215,717",제 21 기,2019.01.01 ~ 2019.12.31,"-38,757,201",26,USD
2394,1245062,코오롱티슈진,950160,2021,20220321001506,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 23 기,2021.01.01 ~ 2021.12.31,"-41,201,076",제 22 기,2020.01.01 ~ 2020.12.31,"-35,307,618",제 21 기,2019.01.01 ~ 2019.12.31,"-42,840,351",28,USD
2395,1245062,코오롱티슈진,950160,2021,20220321001506,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 23 기,2021.01.01 ~ 2021.12.31,"-41,391,802",제 22 기,2020.01.01 ~ 2020.12.31,"-35,412,429",제 21 기,2019.01.01 ~ 2019.12.31,"-42,884,761",30,USD
2396,1245062,코오롱티슈진,950160,2021,20220321001506,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 23 기,2021.01.01 ~ 2021.12.31,"-41,391,802",제 22 기,2020.01.01 ~ 2020.12.31,"-35,412,429",제 21 기,2019.01.01 ~ 2019.12.31,"-42,884,761",62,USD
2406,1245062,코오롱티슈진,950160,2022,20230320000716,11011,CFS,재무제표,IS,손익계산서,매출액,제 24 기,2022.01.01 ~ 2022.12.31,"7,319,202",제 23 기,2021.01.01 ~ 2021.12.31,"3,497,973",제 22 기,2020.01.01 ~ 2020.12.31,"3,013,298",24,USD
2407,1245062,코오롱티슈진,950160,2022,20230320000716,11011,CFS,재무제표,IS,손익계산서,영업이익,제 24 기,2022.01.01 ~ 2022.12.31,"-12,618,990",제 23 기,2021.01.01 ~ 2021.12.31,"-40,984,035",제 22 기,2020.01.01 ~ 2020.12.31,"-35,215,717",26,USD
2408,1245062,코오롱티슈진,950160,2022,20230320000716,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 24 기,2022.01.01 ~ 2022.12.31,"-7,601,402",제 23 기,2021.01.01 ~ 2021.12.31,"-41,201,076",제 22 기,2020.01.01 ~ 2020.12.31,"-35,307,618",28,USD
2409,1245062,코오롱티슈진,950160,2022,20230320000716,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 24 기,2022.01.01 ~ 2022.12.31,"-8,619,693",제 23 기,2021.01.01 ~ 2021.12.31,"-41,391,802",제 22 기,2020.01.01 ~ 2020.12.31,"-35,412,429",30,USD
2410,1245062,코오롱티슈진,950160,2022,20230320000716,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 24 기,2022.01.01 ~ 2022.12.31,"-8,619,693",제 23 기,2021.01.01 ~ 2021.12.31,"-41,391,802",제 22 기,2020.01.01 ~ 2020.12.31,"-35,412,429",62,USD
2420,1245062,코오롱티슈진,950160,2023,20240320002010,11011,CFS,재무제표,IS,손익계산서,매출액,제 25 기,2023.01.01 ~ 2023.12.31,"2,839,000",제 24 기,2022.01.01 ~ 2022.12.31,"7,319,202",제 23 기,2021.01.01 ~ 2021.12.31,"3,497,973",24,USD
2421,1245062,코오롱티슈진,950160,2023,20240320002010,11011,CFS,재무제표,IS,손익계산서,영업이익,제 25 기,2023.01.01 ~ 2023.12.31,"-15,707,145",제 24 기,2022.01.01 ~ 2022.12.31,"-12,618,990",제 23 기,2021.01.01 ~ 2021.12.31,"-40,984,035",26,USD
2422,1245062,코오롱티슈진,950160,2023,20240320002010,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 25 기,2023.01.01 ~ 2023.12.31,"-13,000,678",제 24 기,2022.01.01 ~ 2022.12.31,"-7,601,402",제 23 기,2021.01.01 ~ 2021.12.31,"-41,201,076",28,USD
2423,1245062,코오롱티슈진,950160,2023,20240320002010,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 25 기,2023.01.01 ~ 2023.12.31,"-13,194,601",제 24 기,2022.01.01 ~ 2022.12.31,"-8,619,693",제 23 기,2021.01.01 ~ 2021.12.31,"-41,391,802",30,USD
2424,1245062,코오롱티슈진,950160,2023,20240320002010,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 25 기,2023.01.01 ~ 2023.12.31,"-13,194,601",제 24 기,2022.01.01 ~ 2022.12.31,"-8,619,693",제 23 기,2021.01.01 ~ 2021.12.31,"-41,391,802",62,USD
2425,1245062,코오롱티슈진,950160,2023,20240320002010,11011,CFS,재무제표,IS,손익계산서,총포괄손익,제 25 기,2023.01.01 ~ 2023.12.31,"-13,198,567",제 24 기,2022.01.01 ~ 2022.12.31,"-8,658,714",제 23 기,2021.01.01 ~ 2021.12.31,"-41,524,595",64,USD
2435,1041828,JTC,950170,2018,20180628000516,11011,CFS,재무제표,IS,손익계산서,매출액,제 24 기,2017.03.01 ~ 2018.02.28,"53,192,674,000",제 23 기,2016.03.01 ~ 2017.02.28,"50,055,219,000",제 22 기,2015.03.01 ~ 2016.02.29,"65,823,135,000",24,JPY
2436,1041828,JTC,950170,2018,20180628000516,11011,CFS,재무제표,IS,손익계산서,영업이익,제 24 기,2017.03.01 ~ 2018.02.28,"3,130,085,000",제 23 기,2016.03.01 ~ 2017.02.28,"2,518,629,000",제 22 기,2015.03.01 ~ 2016.02.29,"9,456,403,000",26,JPY
2437,1041828,JTC,950170,2018,20180628000516,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 24 기,2017.03.01 ~ 2018.02.28,"3,079,863,000",제 23 기,2016.03.01 ~ 2017.02.28,"2,468,574,000",제 22 기,2015.03.01 ~ 2016.02.29,"9,509,224,000",28,JPY
2438,1041828,JTC,950170,2018,20180628000516,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 24 기,2017.03.01 ~ 2018.02.28,"2,452,572,000",제 23 기,2016.03.01 ~ 2017.02.28,"1,400,497,000",제 22 기,2015.03.01 ~ 2016.02.29,"6,318,661,000",30,JPY
2439,1041828,JTC,950170,2018,20180628000516,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 24 기,2017.03.01 ~ 2018.02.28,"2,452,572,000",제 23 기,2016.03.01 ~ 2017.02.28,"1,400,497,000",제 22 기,2015.03.01 ~ 2016.02.29,"6,318,661,000",62,JPY
2463,1041828,JTC,950170,2019,20200120000265,11011,CFS,재무제표,IS,손익계산서,매출액,제 25 기,2018.03.01 ~ 2019.02.28,"49,192,196,674",제 24 기,2017.03.01 ~ 2018.02.28,"53,192,674,259",제 23 기,2016.03.01 ~ 2017.02.28,"50,055,218,833",24,JPY
2464,1041828,JTC,950170,2019,20200120000265,11011,CFS,재무제표,IS,손익계산서,영업이익,제 25 기,2018.03.01 ~ 2019.02.28,"2,466,712,295",제 24 기,2017.03.01 ~ 2018.02.28,"3,130,085,199",제 23 기,2016.03.01 ~ 2017.02.28,"2,518,630,362",26,JPY
2465,1041828,JTC,950170,2019,20200120000265,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 25 기,2018.03.01 ~ 2019.02.28,"2,430,570,896",제 24 기,2017.03.01 ~ 2018.02.28,"3,079,863,285",제 23 기,2016.03.01 ~ 2017.02.28,"2,468,574,953",28,JPY
2466,1041828,JTC,950170,2019,20200120000265,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 25 기,2018.03.01 ~ 2019.02.28,"1,546,978,643",제 24 기,2017.03.01 ~ 2018.02.28,"2,452,572,363",제 23 기,2016.03.01 ~ 2017.02.28,"1,400,497,212",30,JPY
2467,1041828,JTC,950170,2019,20200120000265,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 25 기,2018.03.01 ~ 2019.02.28,"1,546,978,643",제 24 기,2017.03.01 ~ 2018.02.28,"2,452,572,363",제 23 기,2016.03.01 ~ 2017.02.28,"1,400,497,212",62,JPY
2491,1041828,JTC,950170,2020,20200629000481,11011,CFS,재무제표,IS,손익계산서,매출액,제 26 기,2019.03.01 ~ 2020.02.29,"44,916,042,612",제 25 기,2018.03.01 ~ 2019.02.28,"49,192,196,674",제 24 기,2017.03.01 ~ 2018.02.28,"53,192,674,259",24,JPY
2492,1041828,JTC,950170,2020,20200629000481,11011,CFS,재무제표,IS,손익계산서,영업이익,제 26 기,2019.03.01 ~ 2020.02.29,"1,441,872,745",제 25 기,2018.03.01 ~ 2019.02.28,"2,466,712,295",제 24 기,2017.03.01 ~ 2018.02.28,"3,130,085,199",26,JPY
2493,1041828,JTC,950170,2020,20200629000481,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 26 기,2019.03.01 ~ 2020.02.29,"-1,303,622,769",제 25 기,2018.03.01 ~ 2019.02.28,"2,430,570,896",제 24 기,2017.03.01 ~ 2018.02.28,"3,079,863,285",28,JPY
2494,1041828,JTC,950170,2020,20200629000481,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 26 기,2019.03.01 ~ 2020.02.29,"-2,055,957,811",제 25 기,2018.03.01 ~ 2019.02.28,"1,546,978,643",제 24 기,2017.03.01 ~ 2018.02.28,"2,452,572,363",30,JPY
2495,1041828,JTC,950170,2020,20200629000481,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 26 기,2019.03.01 ~ 2020.02.29,"-2,055,957,811",제 25 기,2018.03.01 ~ 2019.02.28,"1,546,978,643",제 24 기,2017.03.01 ~ 2018.02.28,"2,452,572,363",62,JPY
2519,1041828,JTC,950170,2021,20210528000522,11011,CFS,재무제표,IS,손익계산서,매출액,제 27 기,2020.03.01 ~ 2021.02.28,"1,333,411,931",제 26 기,2019.03.01 ~ 2020.02.29,"44,916,042,612",제 25 기,2018.03.01 ~ 2019.02.28,"49,192,196,674",24,JPY
2520,1041828,JTC,950170,2021,20210528000522,11011,CFS,재무제표,IS,손익계산서,영업이익,제 27 기,2020.03.01 ~ 2021.02.28,"-8,800,666,280",제 26 기,2019.03.01 ~ 2020.02.29,"1,441,872,745",제 25 기,2018.03.01 ~ 2019.02.28,"2,466,712,295",26,JPY
2521,1041828,JTC,950170,2021,20210528000522,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 27 기,2020.03.01 ~ 2021.02.28,"-8,774,417,678",제 26 기,2019.03.01 ~ 2020.02.29,"-1,303,622,769",제 25 기,2018.03.01 ~ 2019.02.28,"2,430,570,896",28,JPY
2522,1041828,JTC,950170,2021,20210528000522,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 27 기,2020.03.01 ~ 2021.02.28,"-9,281,442,835",제 26 기,2019.03.01 ~ 2020.02.29,"-2,055,957,811",제 25 기,2018.03.01 ~ 2019.02.28,"1,546,978,643",30,JPY
2523,1041828,JTC,950170,2021,20210528000522,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 27 기,2020.03.01 ~ 2021.02.28,"-9,281,442,835",제 26 기,2019.03.01 ~ 2020.02.29,"-2,055,957,811",제 25 기,2018.03.01 ~ 2019.02.28,"1,546,978,643",62,JPY
2547,1041828,JTC,950170,2023,20230526000592,11011,CFS,재무제표,IS,손익계산서,매출액,제 29 기,2022.03.01 ~ 2023.02.28,"3,176,844,596",제 28 기,2021.03.01 ~ 2022.02.28,"1,218,543,889",제 27 기,2020.03.01 ~ 2021.02.28,"1,333,411,931",24,JPY
2548,1041828,JTC,950170,2023,20230526000592,11011,CFS,재무제표,IS,손익계산서,영업이익,제 29 기,2022.03.01 ~ 2023.02.28,"-1,562,354,640",제 28 기,2021.03.01 ~ 2022.02.28,"-8,678,238,947",제 27 기,2020.03.01 ~ 2021.02.28,"-8,800,666,280",26,JPY
2549,1041828,JTC,950170,2023,20230526000592,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 29 기,2022.03.01 ~ 2023.02.28,"-1,357,925,233",제 28 기,2021.03.01 ~ 2022.02.28,"-8,872,786,259",제 27 기,2020.03.01 ~ 2021.02.28,"-8,774,417,678",28,JPY
2550,1041828,JTC,950170,2023,20230526000592,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 29 기,2022.03.01 ~ 2023.02.28,"-1,343,999,344",제 28 기,2021.03.01 ~ 2022.02.28,"-8,866,981,305",제 27 기,2020.03.01 ~ 2021.02.28,"-9,281,442,835",30,JPY
2551,1041828,JTC,950170,2023,20230526000592,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 29 기,2022.03.01 ~ 2023.02.28,"-1,343,999,344",제 28 기,2021.03.01 ~ 2022.02.28,"-8,866,981,305",제 27 기,2020.03.01 ~ 2021.02.28,"-9,281,442,835",62,JPY
2575,1041828,JTC,950170,2022,20220530000285,11011,CFS,재무제표,IS,손익계산서,매출액,제 28 기,2021.03.01 ~ 2022.02.28,"1,218,543,889",제 27 기,2020.03.01 ~ 2021.02.28,"1,333,411,931",제 26 기,2019.03.01 ~ 2020.02.29,"44,916,042,612",24,JPY
2576,1041828,JTC,950170,2022,20220530000285,11011,CFS,재무제표,IS,손익계산서,영업이익,제 28 기,2021.03.01 ~ 2022.02.28,"-8,678,238,947",제 27 기,2020.03.01 ~ 2021.02.28,"-8,800,666,280",제 26 기,2019.03.01 ~ 2020.02.29,"1,441,872,745",26,JPY
2577,1041828,JTC,950170,2022,20220530000285,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 28 기,2021.03.01 ~ 2022.02.28,"-8,872,786,259",제 27 기,2020.03.01 ~ 2021.02.28,"-8,774,417,678",제 26 기,2019.03.01 ~ 2020.02.29,"-1,303,622,769",28,JPY
2578,1041828,JTC,950170,2022,20220530000285,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 28 기,2021.03.01 ~ 2022.02.28,"-8,866,981,305",제 27 기,2020.03.01 ~ 2021.02.28,"-9,281,442,835",제 26 기,2019.03.01 ~ 2020.02.29,"-2,055,957,811",30,JPY
2579,1041828,JTC,950170,2022,20220530000285,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 28 기,2021.03.01 ~ 2022.02.28,"-8,866,981,305",제 27 기,2020.03.01 ~ 2021.02.28,"-9,281,442,835",제 26 기,2019.03.01 ~ 2020.02.29,"-2,055,957,811",62,JPY
2601,1338724,에스앤케이,950180,2020,20201130001170,11011,CFS,재무제표,IS,손익계산서,매출액,제 19 기,2019.08.01 ~ 2020.07.31,"5,432,267,862",제 18 기,2018.08.01 ~ 2019.07.31,"8,804,201,125",제 17 기,2017.08.01 ~ 2018.07.31,"6,171,985,851",24,JPY
2602,1338724,에스앤케이,950180,2020,20201130001170,11011,CFS,재무제표,IS,손익계산서,영업이익,제 19 기,2019.08.01 ~ 2020.07.31,"1,547,672,205",제 18 기,2018.08.01 ~ 2019.07.31,"3,873,437,545",제 17 기,2017.08.01 ~ 2018.07.31,"3,206,188,641",26,JPY
2603,1338724,에스앤케이,950180,2020,20201130001170,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 19 기,2019.08.01 ~ 2020.07.31,"2,234,374,713",제 18 기,2018.08.01 ~ 2019.07.31,"3,451,651,823",제 17 기,2017.08.01 ~ 2018.07.31,"3,307,331,009",28,JPY
2604,1338724,에스앤케이,950180,2020,20201130001170,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 19 기,2019.08.01 ~ 2020.07.31,"1,758,398,688",제 18 기,2018.08.01 ~ 2019.07.31,"2,686,752,710",제 17 기,2017.08.01 ~ 2018.07.31,-,30,JPY
2605,1338724,에스앤케이,950180,2020,20201130001170,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 19 기,2019.08.01 ~ 2020.07.31,"1,758,398,688",제 18 기,2018.08.01 ~ 2019.07.31,"2,686,752,710",제 17 기,2017.08.01 ~ 2018.07.31,-,62,JPY
2627,1338724,에스앤케이,950180,2019,20191128000650,11011,CFS,재무제표,IS,손익계산서,매출액,제 18 기,2018.08.01 ~ 2019.07.31,"8,804,201,125",제 17 기,2017.08.01 ~ 2018.07.31,"6,171,985,851",제 16 기,2016.08.01 ~ 2017.07.31,"4,950,162,095",24,JPY
2628,1338724,에스앤케이,950180,2019,20191128000650,11011,CFS,재무제표,IS,손익계산서,영업이익,제 18 기,2018.08.01 ~ 2019.07.31,"3,873,437,545",제 17 기,2017.08.01 ~ 2018.07.31,"3,206,188,641",제 16 기,2016.08.01 ~ 2017.07.31,"2,844,816,919",26,JPY
2629,1338724,에스앤케이,950180,2019,20191128000650,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 18 기,2018.08.01 ~ 2019.07.31,"3,451,651,823",제 17 기,2017.08.01 ~ 2018.07.31,"3,307,331,009",제 16 기,2016.08.01 ~ 2017.07.31,"2,956,736,413",28,JPY
2630,1338724,에스앤케이,950180,2019,20191128000650,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 18 기,2018.08.01 ~ 2019.07.31,"2,686,752,710",제 17 기,2017.08.01 ~ 2018.07.31,"2,290,688,976",제 16 기,2016.08.01 ~ 2017.07.31,"2,810,156,632",30,JPY
2631,1338724,에스앤케이,950180,2019,20191128000650,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 18 기,2018.08.01 ~ 2019.07.31,"2,686,752,710",제 17 기,2017.08.01 ~ 2018.07.31,"2,290,688,976",제 16 기,2016.08.01 ~ 2017.07.31,"2,810,156,632",62,JPY
2653,1338724,에스앤케이,950180,2021,20211123000349,11011,CFS,재무제표,IS,손익계산서,매출액,제 20 기,2020.08.01 ~ 2021.07.31,"4,055,073,694",제 19 기,2019.08.01 ~ 2020.07.31,"5,432,267,862",제 18 기,2018.08.01 ~ 2019.07.31,"8,804,201,125",24,JPY
2654,1338724,에스앤케이,950180,2021,20211123000349,11011,CFS,재무제표,IS,손익계산서,영업이익,제 20 기,2020.08.01 ~ 2021.07.31,"664,792,534",제 19 기,2019.08.01 ~ 2020.07.31,"1,547,672,205",제 18 기,2018.08.01 ~ 2019.07.31,"3,873,437,545",26,JPY
2655,1338724,에스앤케이,950180,2021,20211123000349,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 20 기,2020.08.01 ~ 2021.07.31,"-46,830,007",제 19 기,2019.08.01 ~ 2020.07.31,"2,234,374,713",제 18 기,2018.08.01 ~ 2019.07.31,"3,451,651,823",28,JPY
2656,1338724,에스앤케이,950180,2021,20211123000349,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 20 기,2020.08.01 ~ 2021.07.31,"-97,035,568",제 19 기,2019.08.01 ~ 2020.07.31,"1,758,398,688",제 18 기,2018.08.01 ~ 2019.07.31,"2,686,752,710",30,JPY
2657,1338724,에스앤케이,950180,2021,20211123000349,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 20 기,2020.08.01 ~ 2021.07.31,"-97,035,568",제 19 기,2019.08.01 ~ 2020.07.31,"1,758,398,688",제 18 기,2018.08.01 ~ 2019.07.31,"2,686,752,710",62,JPY
2679,1338724,에스앤케이,950180,2022,20221125000109,11011,CFS,재무제표,IS,손익계산서,매출액,제 21 기,2021.08.01 ~ 2022.07.31,"5,106,102,630",제 20 기,2020.08.01 ~ 2021.07.31,"4,055,073,694",제 19 기,2019.08.01 ~ 2020.07.31,"5,432,267,862",24,JPY
2680,1338724,에스앤케이,950180,2022,20221125000109,11011,CFS,재무제표,IS,손익계산서,영업이익,제 21 기,2021.08.01 ~ 2022.07.31,"918,256,109",제 20 기,2020.08.01 ~ 2021.07.31,"664,792,534",제 19 기,2019.08.01 ~ 2020.07.31,"1,547,672,205",26,JPY
2681,1338724,에스앤케이,950180,2022,20221125000109,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 21 기,2021.08.01 ~ 2022.07.31,"2,331,520,884",제 20 기,2020.08.01 ~ 2021.07.31,"-46,830,007",제 19 기,2019.08.01 ~ 2020.07.31,"2,234,374,713",28,JPY
2682,1338724,에스앤케이,950180,2022,20221125000109,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 21 기,2021.08.01 ~ 2022.07.31,"1,044,387,894",제 20 기,2020.08.01 ~ 2021.07.31,"-97,035,568",제 19 기,2019.08.01 ~ 2020.07.31,"1,758,398,688",30,JPY
2683,1338724,에스앤케이,950180,2022,20221125000109,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 21 기,2021.08.01 ~ 2022.07.31,"1,044,387,894",제 20 기,2020.08.01 ~ 2021.07.31,"-97,035,568",제 19 기,2019.08.01 ~ 2020.07.31,"1,758,398,688",62,JPY
2707,1416235,고스트스튜디오,950190,2020,20210318001249,11011,CFS,재무제표,IS,손익계산서,매출액,제 5 기,2020.01.01 ~ 2020.12.31,"742,445,216",제 4 기,2019.01.01 ~ 2019.12.31,"651,651,888",제 3 기,2018.01.01 ~ 2018.12.31,"566,021,065",24,HKD
2708,1416235,고스트스튜디오,950190,2020,20210318001249,11011,CFS,재무제표,IS,손익계산서,영업이익,제 5 기,2020.01.01 ~ 2020.12.31,"300,298,247",제 4 기,2019.01.01 ~ 2019.12.31,"283,403,701",제 3 기,2018.01.01 ~ 2018.12.31,"227,384,734",26,HKD
2709,1416235,고스트스튜디오,950190,2020,20210318001249,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 5 기,2020.01.01 ~ 2020.12.31,"301,293,067",제 4 기,2019.01.01 ~ 2019.12.31,"282,761,122",제 3 기,2018.01.01 ~ 2018.12.31,"227,803,921",28,HKD
2710,1416235,고스트스튜디오,950190,2020,20210318001249,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 5 기,2020.01.01 ~ 2020.12.31,"247,634,888",제 4 기,2019.01.01 ~ 2019.12.31,"232,002,058",제 3 기,2018.01.01 ~ 2018.12.31,"189,096,838",30,HKD
2711,1416235,고스트스튜디오,950190,2020,20210318001249,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 5 기,2020.01.01 ~ 2020.12.31,"247,634,888",제 4 기,2019.01.01 ~ 2019.12.31,"232,002,058",제 3 기,2018.01.01 ~ 2018.12.31,"189,096,838",62,HKD
2735,1416235,고스트스튜디오,950190,2021,20220322000873,11011,CFS,재무제표,IS,손익계산서,매출액,제 6 기,2021.01.01 ~ 2021.12.31,"638,460,759",제 5 기,2020.01.01 ~ 2020.12.31,"742,445,216",제 4 기,2019.01.01 ~ 2019.12.31,"651,651,888",24,HKD
2736,1416235,고스트스튜디오,950190,2021,20220322000873,11011,CFS,재무제표,IS,손익계산서,영업이익,제 6 기,2021.01.01 ~ 2021.12.31,"236,331,776",제 5 기,2020.01.01 ~ 2020.12.31,"300,298,247",제 4 기,2019.01.01 ~ 2019.12.31,"283,403,701",26,HKD
2737,1416235,고스트스튜디오,950190,2021,20220322000873,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 6 기,2021.01.01 ~ 2021.12.31,"235,035,165",제 5 기,2020.01.01 ~ 2020.12.31,"301,293,067",제 4 기,2019.01.01 ~ 2019.12.31,"282,761,122",28,HKD
2738,1416235,고스트스튜디오,950190,2021,20220322000873,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 6 기,2021.01.01 ~ 2021.12.31,"193,094,463",제 5 기,2020.01.01 ~ 2020.12.31,"247,634,888",제 4 기,2019.01.01 ~ 2019.12.31,"232,002,058",30,HKD
2739,1416235,고스트스튜디오,950190,2021,20220322000873,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 6 기,2021.01.01 ~ 2021.12.31,"193,094,463",제 5 기,2020.01.01 ~ 2020.12.31,"247,634,888",제 4 기,2019.01.01 ~ 2019.12.31,"232,002,058",62,HKD
2763,1416235,고스트스튜디오,950190,2022,20230322001333,11011,CFS,재무제표,IS,손익계산서,매출액,제 7 기,2022.01.01 ~ 2022.12.31,"72,276,381",제 6 기,2021.01.01 ~ 2021.12.31,"82,126,646",제 5 기,2020.01.01 ~ 2020.12.31,"95,724,039",24,USD
2764,1416235,고스트스튜디오,950190,2022,20230322001333,11011,CFS,재무제표,IS,손익계산서,영업이익,제 7 기,2022.01.01 ~ 2022.12.31,"22,699,458",제 6 기,2021.01.01 ~ 2021.12.31,"30,399,889",제 5 기,2020.01.01 ~ 2020.12.31,"38,717,686",26,USD
2765,1416235,고스트스튜디오,950190,2022,20230322001333,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 7 기,2022.01.01 ~ 2022.12.31,"23,313,182",제 6 기,2021.01.01 ~ 2021.12.31,"30,233,103",제 5 기,2020.01.01 ~ 2020.12.31,"38,845,949",28,USD
2766,1416235,고스트스튜디오,950190,2022,20230322001333,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 7 기,2022.01.01 ~ 2022.12.31,"19,253,814",제 6 기,2021.01.01 ~ 2021.12.31,"24,838,176",제 5 기,2020.01.01 ~ 2020.12.31,"31,927,758",30,USD
2767,1416235,고스트스튜디오,950190,2022,20230322001333,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 7 기,2022.01.01 ~ 2022.12.31,"19,253,814",제 6 기,2021.01.01 ~ 2021.12.31,"24,838,176",제 5 기,2020.01.01 ~ 2020.12.31,"31,927,758",62,USD
2792,1416235,고스트스튜디오,950190,2023,20241025000138,11011,CFS,재무제표,IS,손익계산서,매출액,제 8 기,2023.01.01 ~ 2023.12.31,"64,927,510",제 7 기,2022.01.01 ~ 2022.12.31,"72,276,381",제 6 기,2021.01.01 ~ 2021.12.31,"82,126,646",24,USD
2793,1416235,고스트스튜디오,950190,2023,20241025000138,11011,CFS,재무제표,IS,손익계산서,영업이익,제 8 기,2023.01.01 ~ 2023.12.31,"19,692,380",제 7 기,2022.01.01 ~ 2022.12.31,"22,699,458",제 6 기,2021.01.01 ~ 2021.12.31,"30,399,889",26,USD
2794,1416235,고스트스튜디오,950190,2023,20241025000138,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 8 기,2023.01.01 ~ 2023.12.31,"17,751,485",제 7 기,2022.01.01 ~ 2022.12.31,"23,313,182",제 6 기,2021.01.01 ~ 2021.12.31,"30,233,103",28,USD
2795,1416235,고스트스튜디오,950190,2023,20241025000138,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 8 기,2023.01.01 ~ 2023.12.31,"14,283,065",제 7 기,2022.01.01 ~ 2022.12.31,"19,253,814",제 6 기,2021.01.01 ~ 2021.12.31,"24,838,176",30,USD
2796,1416235,고스트스튜디오,950190,2023,20241025000138,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 8 기,2023.01.01 ~ 2023.12.31,"14,283,065",제 7 기,2022.01.01 ~ 2022.12.31,"19,253,814",제 6 기,2021.01.01 ~ 2021.12.31,"24,838,176",62,USD
2797,1416235,고스트스튜디오,950190,2023,20241025000138,11011,CFS,재무제표,IS,손익계산서,총포괄손익,제 8 기,2023.01.01 ~ 2023.12.31,"14,283,065",제 7 기,2022.01.01 ~ 2022.12.31,"19,253,814",제 6 기,2021.01.01 ~ 2021.12.31,"25,366,098",64,USD
2807,1442115,소마젠,950200,2020,20210323001016,11011,CFS,재무제표,IS,손익계산서,매출액,제 17 기,2020.01.01 ~ 2020.12.31,"16,105,984",제 16 기,2019.01.01 ~ 2019.12.31,"17,232,301",제 15 기,2018.01.01 ~ 2018.12.31,"18,972,972",24,USD
2808,1442115,소마젠,950200,2020,20210323001016,11011,CFS,재무제표,IS,손익계산서,영업이익,제 17 기,2020.01.01 ~ 2020.12.31,"-8,705,863",제 16 기,2019.01.01 ~ 2019.12.31,"-4,167,226",제 15 기,2018.01.01 ~ 2018.12.31,"-2,763,500",26,USD
2809,1442115,소마젠,950200,2020,20210323001016,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 17 기,2020.01.01 ~ 2020.12.31,"-18,289,561",제 16 기,2019.01.01 ~ 2019.12.31,"-19,791,200",제 15 기,2018.01.01 ~ 2018.12.31,"-2,344,329",28,USD
2810,1442115,소마젠,950200,2020,20210323001016,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 17 기,2020.01.01 ~ 2020.12.31,"-18,291,850",제 16 기,2019.01.01 ~ 2019.12.31,"-19,788,834",제 15 기,2018.01.01 ~ 2018.12.31,"-2,345,760",30,USD
2811,1442115,소마젠,950200,2020,20210323001016,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 17 기,2020.01.01 ~ 2020.12.31,"-18,291,850",제 16 기,2019.01.01 ~ 2019.12.31,"-19,788,834",제 15 기,2018.01.01 ~ 2018.12.31,"-2,345,760",62,USD
2821,1442115,소마젠,950200,2021,20220323001175,11011,CFS,재무제표,IS,손익계산서,매출액,제 18 기,2021.01.01 ~ 2021.12.31,"24,983,530",제 17 기,2020.01.01 ~ 2020.12.31,"16,105,984",제 16 기,2019.01.01 ~ 2019.12.31,"17,232,301",24,USD
2822,1442115,소마젠,950200,2021,20220323001175,11011,CFS,재무제표,IS,손익계산서,영업이익,제 18 기,2021.01.01 ~ 2021.12.31,"-6,757,879",제 17 기,2020.01.01 ~ 2020.12.31,"-8,705,863",제 16 기,2019.01.01 ~ 2019.12.31,"-4,167,226",26,USD
2823,1442115,소마젠,950200,2021,20220323001175,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 18 기,2021.01.01 ~ 2021.12.31,"-6,166,469",제 17 기,2020.01.01 ~ 2020.12.31,"-18,289,561",제 16 기,2019.01.01 ~ 2019.12.31,"-19,791,200",28,USD
2824,1442115,소마젠,950200,2021,20220323001175,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 18 기,2021.01.01 ~ 2021.12.31,"-6,170,351",제 17 기,2020.01.01 ~ 2020.12.31,"-18,291,850",제 16 기,2019.01.01 ~ 2019.12.31,"-19,788,834",30,USD
2825,1442115,소마젠,950200,2021,20220323001175,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 18 기,2021.01.01 ~ 2021.12.31,"-6,170,351",제 17 기,2020.01.01 ~ 2020.12.31,"-18,291,850",제 16 기,2019.01.01 ~ 2019.12.31,"-19,788,834",62,USD
2850,1442115,소마젠,950200,2023,20240321001854,11011,CFS,재무제표,IS,손익계산서,매출액,제 20 기,2023.01.01 ~ 2023.12.31,"24,718,849",제 19 기,2022.01.01 ~ 2022.12.31,"33,572,854",제 18 기,2021.01.01 ~ 2021.12.31,"24,983,530",24,USD
2851,1442115,소마젠,950200,2023,20240321001854,11011,CFS,재무제표,IS,손익계산서,영업이익,제 20 기,2023.01.01 ~ 2023.12.31,"-2,403,944",제 19 기,2022.01.01 ~ 2022.12.31,"-1,141,416",제 18 기,2021.01.01 ~ 2021.12.31,"-6,757,879",26,USD
2852,1442115,소마젠,950200,2023,20240321001854,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 20 기,2023.01.01 ~ 2023.12.31,"-3,050,862",제 19 기,2022.01.01 ~ 2022.12.31,"-998,137",제 18 기,2021.01.01 ~ 2021.12.31,"-6,937,536",28,USD
2853,1442115,소마젠,950200,2023,20240321001854,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 20 기,2023.01.01 ~ 2023.12.31,"-3,057,930",제 19 기,2022.01.01 ~ 2022.12.31,"-1,002,751",제 18 기,2021.01.01 ~ 2021.12.31,"-6,941,418",30,USD
2854,1442115,소마젠,950200,2023,20240321001854,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 20 기,2023.01.01 ~ 2023.12.31,"-3,057,930",제 19 기,2022.01.01 ~ 2022.12.31,"-1,002,751",제 18 기,2021.01.01 ~ 2021.12.31,"-6,941,418",62,USD
2855,1442115,소마젠,950200,2023,20240321001854,11011,CFS,재무제표,IS,손익계산서,총포괄손익,제 20 기,2023.01.01 ~ 2023.12.31,"-3,057,930",제 19 기,2022.01.01 ~ 2022.12.31,"-1,002,751",제 18 기,2021.01.01 ~ 2021.12.31,"-6,941,418",64,USD
2865,1442115,소마젠,950200,2022,20230323001319,11011,CFS,재무제표,IS,손익계산서,매출액,제 19 기,2022.01.01 ~ 2022.12.31,"33,572,854",제 18 기,2021.01.01 ~ 2021.12.31,"24,983,530",제 17 기,2020.01.01 ~ 2020.12.31,"16,105,984",24,USD
2866,1442115,소마젠,950200,2022,20230323001319,11011,CFS,재무제표,IS,손익계산서,영업이익,제 19 기,2022.01.01 ~ 2022.12.31,"-1,141,416",제 18 기,2021.01.01 ~ 2021.12.31,"-6,757,879",제 17 기,2020.01.01 ~ 2020.12.31,"-8,705,863",26,USD
2867,1442115,소마젠,950200,2022,20230323001319,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 19 기,2022.01.01 ~ 2022.12.31,"-806,771",제 18 기,2021.01.01 ~ 2021.12.31,"-6,166,469",제 17 기,2020.01.01 ~ 2020.12.31,"-18,289,561",28,USD
2868,1442115,소마젠,950200,2022,20230323001319,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 19 기,2022.01.01 ~ 2022.12.31,"-811,385",제 18 기,2021.01.01 ~ 2021.12.31,"-6,170,351",제 17 기,2020.01.01 ~ 2020.12.31,"-18,291,850",30,USD
2869,1442115,소마젠,950200,2022,20230323001319,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 19 기,2022.01.01 ~ 2022.12.31,"-811,385",제 18 기,2021.01.01 ~ 2021.12.31,"-6,170,351",제 17 기,2020.01.01 ~ 2020.12.31,"-18,291,850",62,USD
2893,1510489,프레스티지바이오파마,950210,2023,20231129001041,11011,CFS,재무제표,IS,손익계산서,매출액,제 8 기,2022.07.01 ~ 2023.06.30,0,제 7 기,2021.07.01 ~ 2022.06.30,0,제 6 기,2020.07.01 ~ 2021.06.30,0,24,USD
2894,1510489,프레스티지바이오파마,950210,2023,20231129001041,11011,CFS,재무제표,IS,손익계산서,영업이익,제 8 기,2022.07.01 ~ 2023.06.30,"-15,653,952",제 7 기,2021.07.01 ~ 2022.06.30,"-19,564,926",제 6 기,2020.07.01 ~ 2021.06.30,"-15,406,359",26,USD
2895,1510489,프레스티지바이오파마,950210,2023,20231129001041,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 8 기,2022.07.01 ~ 2023.06.30,"22,121,814",제 7 기,2021.07.01 ~ 2022.06.30,"-143,554,167",제 6 기,2020.07.01 ~ 2021.06.30,"-5,566,699",28,USD
2896,1510489,프레스티지바이오파마,950210,2023,20231129001041,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 8 기,2022.07.01 ~ 2023.06.30,"21,519,439",제 7 기,2021.07.01 ~ 2022.06.30,"-144,204,671",제 6 기,2020.07.01 ~ 2021.06.30,"-5,596,699",30,USD
2897,1510489,프레스티지바이오파마,950210,2023,20231129001041,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 8 기,2022.07.01 ~ 2023.06.30,"21,519,439",제 7 기,2021.07.01 ~ 2022.06.30,"-144,204,671",제 6 기,2020.07.01 ~ 2021.06.30,"-5,596,699",62,USD
2898,1510489,프레스티지바이오파마,950210,2023,20231129001041,11011,CFS,재무제표,IS,손익계산서,총포괄손익,제 8 기,2022.07.01 ~ 2023.06.30,"21,519,439",제 7 기,2021.07.01 ~ 2022.06.30,"-144,204,671",제 6 기,2020.07.01 ~ 2021.06.30,"-5,596,699",64,USD
2922,1510489,프레스티지바이오파마,950210,2022,20220920000416,11011,CFS,재무제표,IS,손익계산서,매출액,제 7 기,2021.07.01 ~ 2022.06.30,0,제 6 기,2020.07.01 ~ 2021.06.30,0,제 5 기,2019.07.01 ~ 2020.06.30,0,24,USD
2923,1510489,프레스티지바이오파마,950210,2022,20220920000416,11011,CFS,재무제표,IS,손익계산서,영업이익,제 7 기,2021.07.01 ~ 2022.06.30,"-19,564,926",제 6 기,2020.07.01 ~ 2021.06.30,"-15,406,359",제 5 기,2019.07.01 ~ 2020.06.30,"-8,956,096",26,USD
2924,1510489,프레스티지바이오파마,950210,2022,20220920000416,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 7 기,2021.07.01 ~ 2022.06.30,"-143,554,167",제 6 기,2020.07.01 ~ 2021.06.30,"-5,566,699",제 5 기,2019.07.01 ~ 2020.06.30,"-12,188,427",28,USD
2925,1510489,프레스티지바이오파마,950210,2022,20220920000416,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 7 기,2021.07.01 ~ 2022.06.30,"-144,204,671",제 6 기,2020.07.01 ~ 2021.06.30,"-5,596,699",제 5 기,2019.07.01 ~ 2020.06.30,"-12,270,785",30,USD
2926,1510489,프레스티지바이오파마,950210,2022,20220920000416,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 7 기,2021.07.01 ~ 2022.06.30,"-144,204,671",제 6 기,2020.07.01 ~ 2021.06.30,"-5,596,699",제 5 기,2019.07.01 ~ 2020.06.30,"-12,270,785",62,USD
2950,1510489,프레스티지바이오파마,950210,2021,20210916000175,11011,CFS,재무제표,IS,손익계산서,매출액,제 6 기,2020.07.01 ~ 2021.06.30,0,제 5 기,2019.07.01 ~ 2020.06.30,0,제 4 기,2018.07.01 ~ 2019.06.30,"1,840,000",24,USD
2951,1510489,프레스티지바이오파마,950210,2021,20210916000175,11011,CFS,재무제표,IS,손익계산서,영업이익,제 6 기,2020.07.01 ~ 2021.06.30,"-15,406,359",제 5 기,2019.07.01 ~ 2020.06.30,"-8,956,096",제 4 기,2018.07.01 ~ 2019.06.30,"-3,940,674",26,USD
2952,1510489,프레스티지바이오파마,950210,2021,20210916000175,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 6 기,2020.07.01 ~ 2021.06.30,"-5,566,699",제 5 기,2019.07.01 ~ 2020.06.30,"-12,188,427",제 4 기,2018.07.01 ~ 2019.06.30,"-1,120,140",28,USD
2953,1510489,프레스티지바이오파마,950210,2021,20210916000175,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 6 기,2020.07.01 ~ 2021.06.30,"-5,596,699",제 5 기,2019.07.01 ~ 2020.06.30,"-12,270,785",제 4 기,2018.07.01 ~ 2019.06.30,"-1,285,152",30,USD
2954,1510489,프레스티지바이오파마,950210,2021,20210916000175,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 6 기,2020.07.01 ~ 2021.06.30,"-5,596,699",제 5 기,2019.07.01 ~ 2020.06.30,"-12,270,785",제 4 기,2018.07.01 ~ 2019.06.30,"-1,285,152",62,USD
2978,1511558,네오이뮨텍,950220,2020,20210720000251,11011,CFS,재무제표,IS,손익계산서,매출액,제 7 기,2020.01.01 ~ 2020.12.31,-,제 6 기,2019.01.01 ~ 2019.12.31,-,제 5 기,2018.01.01 ~ 2018.12.31,-,24,USD
2979,1511558,네오이뮨텍,950220,2020,20210720000251,11011,CFS,재무제표,IS,손익계산서,영업이익,제 7 기,2020.01.01 ~ 2020.12.31,"-26,186,578",제 6 기,2019.01.01 ~ 2019.12.31,"-13,758,273",제 5 기,2018.01.01 ~ 2018.12.31,-,26,USD
2980,1511558,네오이뮨텍,950220,2020,20210720000251,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 7 기,2020.01.01 ~ 2020.12.31,"-25,459,889",제 6 기,2019.01.01 ~ 2019.12.31,"-12,010,859",제 5 기,2018.01.01 ~ 2018.12.31,-,28,USD
2981,1511558,네오이뮨텍,950220,2020,20210720000251,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 7 기,2020.01.01 ~ 2020.12.31,"-25,459,889",제 6 기,2019.01.01 ~ 2019.12.31,"-12,010,859",제 5 기,2018.01.01 ~ 2018.12.31,-,30,USD
2982,1511558,네오이뮨텍,950220,2020,20210720000251,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 7 기,2020.01.01 ~ 2020.12.31,"-25,459,889",제 6 기,2019.01.01 ~ 2019.12.31,"-12,010,859",제 5 기,2018.01.01 ~ 2018.12.31,-,62,USD
3006,1511558,네오이뮨텍,950220,2021,20220323000347,11011,CFS,재무제표,IS,손익계산서,매출액,제 8 기,2021.01.01 ~ 2021.12.31,0,제 7 기,2020.01.01 ~ 2020.12.31,0,제 6 기,2019.01.01 ~ 2019.12.31,0,24,USD
3007,1511558,네오이뮨텍,950220,2021,20220323000347,11011,CFS,재무제표,IS,손익계산서,영업이익,제 8 기,2021.01.01 ~ 2021.12.31,"-41,688,374",제 7 기,2020.01.01 ~ 2020.12.31,"-26,186,578",제 6 기,2019.01.01 ~ 2019.12.31,"-13,758,273",26,USD
3008,1511558,네오이뮨텍,950220,2021,20220323000347,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",제 7 기,2020.01.01 ~ 2020.12.31,"-25,459,889",제 6 기,2019.01.01 ~ 2019.12.31,"-12,010,859",28,USD
3009,1511558,네오이뮨텍,950220,2021,20220323000347,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",제 7 기,2020.01.01 ~ 2020.12.31,"-25,459,889",제 6 기,2019.01.01 ~ 2019.12.31,"-12,010,859",30,USD
3010,1511558,네오이뮨텍,950220,2021,20220323000347,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",제 7 기,2020.01.01 ~ 2020.12.31,"-25,459,889",제 6 기,2019.01.01 ~ 2019.12.31,"-12,010,859",62,USD
3034,1511558,네오이뮨텍,950220,2022,20230323000867,11011,CFS,재무제표,IS,손익계산서,매출액,제 9 기,2022.01.01 ~ 2022.12.31,0,제 8 기,2021.01.01 ~ 2021.12.31,0,제 7 기,2020.01.01 ~ 2020.12.31,0,24,USD
3035,1511558,네오이뮨텍,950220,2022,20230323000867,11011,CFS,재무제표,IS,손익계산서,영업이익,제 9 기,2022.01.01 ~ 2022.12.31,"-40,520,764",제 8 기,2021.01.01 ~ 2021.12.31,"-41,688,374",제 7 기,2020.01.01 ~ 2020.12.31,"-26,186,578",26,USD
3036,1511558,네오이뮨텍,950220,2022,20230323000867,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 9 기,2022.01.01 ~ 2022.12.31,"-49,668,190",제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",제 7 기,2020.01.01 ~ 2020.12.31,"-25,459,889",28,USD
3037,1511558,네오이뮨텍,950220,2022,20230323000867,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 9 기,2022.01.01 ~ 2022.12.31,"-49,668,190",제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",제 7 기,2020.01.01 ~ 2020.12.31,"-25,459,889",30,USD
3038,1511558,네오이뮨텍,950220,2022,20230323000867,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 9 기,2022.01.01 ~ 2022.12.31,"-49,668,190",제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",제 7 기,2020.01.01 ~ 2020.12.31,"-25,459,889",62,USD
3063,1511558,네오이뮨텍,950220,2023,20240321001357,11011,CFS,재무제표,IS,손익계산서,매출액,제 10 기,2023.01.01 ~ 2023.12.31,0,제 9 기,2022.01.01 ~ 2022.12.31,0,제 8 기,2021.01.01 ~ 2021.12.31,0,24,USD
3064,1511558,네오이뮨텍,950220,2023,20240321001357,11011,CFS,재무제표,IS,손익계산서,영업이익,제 10 기,2023.01.01 ~ 2023.12.31,"-40,985,304",제 9 기,2022.01.01 ~ 2022.12.31,"-40,520,764",제 8 기,2021.01.01 ~ 2021.12.31,"-41,688,374",26,USD
3065,1511558,네오이뮨텍,950220,2023,20240321001357,11011,CFS,재무제표,IS,손익계산서,법인세차감전 순이익,제 10 기,2023.01.01 ~ 2023.12.31,"-40,321,360",제 9 기,2022.01.01 ~ 2022.12.31,"-49,668,190",제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",28,USD
3066,1511558,네오이뮨텍,950220,2023,20240321001357,11011,CFS,재무제표,IS,손익계산서,당기순이익,제 10 기,2023.01.01 ~ 2023.12.31,"-40,321,360",제 9 기,2022.01.01 ~ 2022.12.31,"-49,668,190",제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",30,USD
3067,1511558,네오이뮨텍,950220,2023,20240321001357,11011,CFS,재무제표,IS,손익계산서,당기순이익(손실),제 10 기,2023.01.01 ~ 2023.12.31,"-40,321,360",제 9 기,2022.01.01 ~ 2022.12.31,"-49,668,190",제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",62,USD
3068,1511558,네오이뮨텍,950220,2023,20240321001357,11011,CFS,재무제표,IS,손익계산서,총포괄손익,제 10 기,2023.01.01 ~ 2023.12.31,"-40,321,360",제 9 기,2022.01.01 ~ 2022.12.31,"-49,668,190",제 8 기,2021.01.01 ~ 2021.12.31,"-42,033,053",64,USD
